DE602004008927D1 - Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen - Google Patents

Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen

Info

Publication number
DE602004008927D1
DE602004008927D1 DE200460008927 DE602004008927T DE602004008927D1 DE 602004008927 D1 DE602004008927 D1 DE 602004008927D1 DE 200460008927 DE200460008927 DE 200460008927 DE 602004008927 T DE602004008927 T DE 602004008927T DE 602004008927 D1 DE602004008927 D1 DE 602004008927D1
Authority
DE
Germany
Prior art keywords
nitrite
tissues
administration
subject
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE200460008927
Other languages
English (en)
Other versions
DE602004008927T2 (de
Inventor
Mark T Gladwin
Alan N Schechter
David J Lefer
Rakesh P Patel
Christian J Hunter
Gordon G Power
Daniel B Kim-Shapiro
Ryszard Pluta
Edward H Oldfield
Iii Richard O Cannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Wake Forest University
UAB Research Foundation
Loma Linda University
Louisiana State University
Original Assignee
US Department of Health and Human Services
Wake Forest University
UAB Research Foundation
Loma Linda University
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Wake Forest University, UAB Research Foundation, Loma Linda University, Louisiana State University filed Critical US Department of Health and Human Services
Publication of DE602004008927D1 publication Critical patent/DE602004008927D1/de
Application granted granted Critical
Publication of DE602004008927T2 publication Critical patent/DE602004008927T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE200460008927 2003-07-09 2004-07-09 Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen Expired - Lifetime DE602004008927T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48595903P 2003-07-09 2003-07-09
US485959P 2003-07-09
US51124403P 2003-10-14 2003-10-14
US511244P 2003-10-14
PCT/US2004/022232 WO2005004884A2 (en) 2003-07-09 2004-07-09 Use of nitrite salts for the treatment of cardiovascular conditions

Publications (2)

Publication Number Publication Date
DE602004008927D1 true DE602004008927D1 (de) 2007-10-25
DE602004008927T2 DE602004008927T2 (de) 2008-06-05

Family

ID=34068230

Family Applications (1)

Application Number Title Priority Date Filing Date
DE200460008927 Expired - Lifetime DE602004008927T2 (de) 2003-07-09 2004-07-09 Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen

Country Status (9)

Country Link
US (5) US9675637B2 (de)
EP (2) EP1653978B1 (de)
JP (3) JP5564157B2 (de)
AT (1) ATE372777T1 (de)
AU (2) AU2004257693B8 (de)
CA (2) CA2536827C (de)
DE (1) DE602004008927T2 (de)
ES (1) ES2294543T3 (de)
WO (2) WO2005007173A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133698B2 (en) * 2000-05-15 2012-03-13 Silver James H Sensors for detecting substances indicative of stroke, ischemia, infection or inflammation
EP3064242A1 (de) 2003-04-28 2016-09-07 Advanced Circulatory Systems Inc. Lüfter und verfahren zur behandlung von kopftrauma und geringer blutzirkulation
EP1653978B1 (de) 2003-07-09 2020-06-03 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Vervendung von nitritsalzen zur behandlung von cardiovaskulären erkrankungen
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
WO2006113540A2 (en) 2005-04-14 2006-10-26 Duke University Use of ntrosylated hemoglobin
US8557300B2 (en) 2005-05-19 2013-10-15 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
EP2099463B1 (de) * 2006-11-07 2014-07-16 The General Hospital Corporation Minderung von vasoaktiver sauerstoffträger-induzierter gefässverengung
US10821132B2 (en) 2007-02-26 2020-11-03 Heartbeet Ltd Compositions of nitrates and methods of use thereof
US11759477B2 (en) 2007-02-26 2023-09-19 Heartbeet Ltd. Compositions of nitrates and methods of use thereof
EP2114417A4 (de) * 2007-02-26 2014-04-02 Heartbeet Ltd Neue verwendung von nitriten, nitraten und zusammensetzungen damit
US10842813B2 (en) 2007-02-26 2020-11-24 Heartbeet Ltd Compositions of nitrates and methods of use thereof
US10835555B2 (en) 2007-02-26 2020-11-17 Heartbeet Ltd Compositions of nitrates and methods of use thereof
JP2010519335A (ja) 2007-02-26 2010-06-03 ルンドベルク，ヨン 運動能力向上組成物及びその使用
US9352111B2 (en) 2007-04-19 2016-05-31 Advanced Circulatory Systems, Inc. Systems and methods to increase survival with favorable neurological function after cardiac arrest
WO2009035550A1 (en) * 2007-09-10 2009-03-19 Duke University Treating patients with subarachnoid hemorrhage
US10426750B1 (en) 2007-09-18 2019-10-01 Thermolife International, Llc Amino acid supplement formulations
US8455531B2 (en) 2007-09-18 2013-06-04 Thermolife International, Llc Amino acid compositions
US10646508B1 (en) 2007-09-18 2020-05-12 Thermolife International, Llc Method of safely administering nitrate dietary supplements and compositions
US10426792B1 (en) 2007-09-18 2019-10-01 Thermolife International, Llc Amino acid compositions
US8569368B2 (en) 2007-09-18 2013-10-29 Thermolife International, Llc Amino acid compounds
US8569369B2 (en) 2007-09-18 2013-10-29 Thermolife International, Llc Amino acid compounds
US10435356B1 (en) 2007-09-18 2019-10-08 Thermolife International, Llc Amino acid compositions
US7777074B2 (en) 2007-09-18 2010-08-17 Thermolife International, Llc Amino acid compounds
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
WO2009038796A1 (en) * 2007-09-20 2009-03-26 Wake Forest University Health Sciences Methods of treatment for hemolysis
WO2009065142A2 (en) * 2007-11-15 2009-05-22 Biomedical Research Foundation Of Northwest Louisiana Use of nitrite salts in chronic ischemia
WO2009086470A2 (en) * 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide - donating compounds and uses thereof
WO2009108777A2 (en) * 2008-02-28 2009-09-03 The Uab Research Foundation Use of nitrite to enhance viability, recovery, and function of transplant specimens
US20100016731A1 (en) * 2008-07-15 2010-01-21 Cardiox Corporation Hemodynamic Detection of Circulatory Anomalies
WO2010035253A1 (en) * 2008-09-28 2010-04-01 Joshua Waldhorn Effective nitric oxide generating preparations
AU2016204616B2 (en) * 2009-02-11 2017-05-11 Hope Medical Enterprise, Inc. D.B.A. Hope Pharmaceuticals Sodium nitrite-containing pharmaceutical compositions
AU2015202300B2 (en) * 2009-02-11 2016-05-26 Hope Medical Enterprise, Inc. D.B.A. Hope Pharmaceuticals Sodium nitrite-containing pharmaceutical compositions
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
US9114109B2 (en) 2009-06-16 2015-08-25 University of Pittsburgh—of the Commonwealth System of Higher Education Five-coordinate neuroglobin and use thereof as a blood substitute
US20120237617A1 (en) * 2009-06-18 2012-09-20 Theravasc Inc. Use of nitrite salts in treating tissue damage
WO2010151150A2 (en) * 2009-06-22 2010-12-29 Charles Eason Formulations for vertebrate pest control
AU2009202685B1 (en) 2009-06-30 2010-08-19 Ino Therapeutics Llc Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
PT2451435T (pt) 2009-07-08 2018-01-15 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Composições farmacêuticas que contêm tiossulfato de sódio
US8273857B2 (en) * 2009-09-22 2012-09-25 Jen-Chang Hsia Compositions and methods of use of neurovascular protective multifunctional polynitroxylated pegylated carboxy hemoglobins for transfusion and critical care medicine
US20130209584A1 (en) * 2009-10-14 2013-08-15 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
CN102686111A (zh) 2009-10-14 2012-09-19 瑟阿瓦斯克有限公司 亚硝酸盐/酯的药物制剂以及其应用
WO2012135623A1 (en) * 2011-03-31 2012-10-04 Theravasc Inc. Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline
EP2696865B1 (de) 2011-04-13 2016-12-21 Thermolife International, LLC Verwendungsverfahren für n-acetyl-beta-alanin
GB201114901D0 (en) 2011-08-26 2011-10-12 King S College London Vascular treatments
WO2013052803A2 (en) * 2011-10-07 2013-04-11 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
AU2012319071B2 (en) 2011-10-07 2017-08-03 Epicentrx, Inc. Organonitro thioether compounds and medical uses thereof
WO2013070592A1 (en) 2011-11-07 2013-05-16 The General Hospital Corporation Treatment of red blood cells
AU2012358977A1 (en) 2011-12-19 2014-07-24 ResQSystems, Inc. Systems and methods for therapeutic intrathoracic pressure regulation
US20140066881A1 (en) * 2012-08-31 2014-03-06 Zoll Medical Corporation Cardiac resuscitation methods and kits
JP6441818B2 (ja) * 2013-02-07 2018-12-19 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 心不全の治療法
EP2958573B1 (de) 2013-02-20 2019-05-08 The Board of Supervisors of the Louisiana State University Mechanical and Agricultural College Pharmazeutische formulierungen aus nitrit und verwendungen davon
US20160008394A1 (en) * 2013-02-28 2016-01-14 Aires Pharmaceuticals, Inc. Inorganic nitrite to improve cardiopulmonary hemodynamics
US10517817B2 (en) * 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
US10265495B2 (en) 2013-11-22 2019-04-23 Zoll Medical Corporation Pressure actuated valve systems and methods
CN104096218B (zh) * 2014-06-05 2017-03-22 董文其 重组人源细胞珠蛋白在制备治疗高血脂症及动脉粥样硬化药物中的应用
WO2016077386A1 (en) 2014-11-10 2016-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Topical sodium nitrite formulation
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
ES2880482T3 (es) 2016-01-11 2021-11-24 Epicentrx Inc Composiciones y métodos para la administración intravenosa de 2-bromo-1-(3,3-dinitroazetidin-1-il)etanona
GB201602959D0 (en) 2016-02-19 2016-04-06 Isis Innovation Use of cerebral nitric oxide donors in the assessment of the extent of brain dyfunction following injury
ES2651717B1 (es) * 2016-07-26 2018-11-16 Lara OLLER DUQUE Solución acuosa cristaloide isotónica
JP7332469B2 (ja) 2016-10-14 2023-08-23 エピセントアールエックス，インコーポレイテッド スルホキシアルキル有機窒素および関連のある化合物ならびに医学における使用のための医薬組成物
US10624921B2 (en) 2016-11-15 2020-04-21 Berkeley Nox Limited Dietary supplements
CA3047041A1 (en) * 2016-12-12 2018-06-21 Aobiome Llc Ammonia oxidizing microorganisms for the regulation of blood pressure
WO2018132371A2 (en) 2017-01-10 2018-07-19 United Therapeutics Corporation Methods and compositions for treating pulmonary hypertension
US11116731B2 (en) 2017-02-20 2021-09-14 Brd. of Sup. of LSU and A &M College Hydrogen sulfide and/or nitrite in the treatment and prevention of atrial fibrillation
IL295119B2 (en) 2017-03-08 2023-10-01 Hope Medical Entpr Inc Dba Hope Pharmaceuticals Intradialytic use of sodium thiosulfate
IL312092A (en) 2017-03-08 2024-06-01 Hope Medical Entpr Inc Dba Hope Pharmaceuticals Intradialytic use of sodium nitrite
CA3069004A1 (en) 2017-07-07 2019-01-10 Epicentrx, Inc. Compositions for parenteral administration of therapeutic agents
WO2019099003A2 (en) * 2017-11-15 2019-05-23 Berkeley Nox Limited Novel dietary supplements
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
JP7469816B2 (ja) * 2019-07-22 2024-04-17 学校法人北里研究所 透析装置
WO2021046456A2 (en) * 2019-09-05 2021-03-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nitrite formulations and uses thereof for the treatment of lung injury
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865942A (en) 1971-04-28 1975-02-11 Rech Applic Scient Sogeras 424 Method of increasing cerebral blood flow
GB1595056A (en) 1976-10-12 1981-08-05 Wellcome Found Pharmaceutical combination
US4163790A (en) 1977-05-11 1979-08-07 A. H. Robins Company, Inc. Method for increasing coronary blood flow in mammals
US4849226A (en) 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
US4650484A (en) 1983-02-03 1987-03-17 Alza Corporation Method for treating ischemic conditions
US5500230A (en) 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
JPH0753358Y2 (ja) 1988-04-08 1995-12-06 株式会社ケンウッド 音響機器の制御回路
US5683668A (en) 1990-09-20 1997-11-04 The United States Of America As Represented By The Department Of Health And Human Services Method of generating nitric oxide gas using nitric oxide complexes
US5263473A (en) 1990-11-05 1993-11-23 The Kendall Company Compression device for the limb
US5570683A (en) 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
EP1516639B2 (de) 1990-12-05 2015-04-15 The General Hospital Corporation Verwendung von NO zur Behandlung der persistenten pulmonaren Hypertonie des Neugeborenen
US5396882A (en) 1992-03-11 1995-03-14 The General Hospital Corporation Generation of nitric oxide from air for medical uses
US5536241A (en) 1990-12-05 1996-07-16 The General Hospital Corporation Methods and devices for relaxing smooth muscle contractions
US5108754A (en) 1991-02-08 1992-04-28 Michael Wilburn Orthomolecular method of treating sickle cell disease
US5177208A (en) 1991-02-08 1993-01-05 Michael Wilburn Orthomolecular method of treating sickle cell disease
US5273875A (en) * 1991-03-22 1993-12-28 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
JP3190340B2 (ja) 1991-09-24 2001-07-23 アメリカ合衆国 酸化窒素供与体プロドラッグとしての求核試薬−酸化窒素付加物の酸素置換誘導体
US6291424B1 (en) 1991-11-14 2001-09-18 Brigham And Women's Hospital Nitrosated and nitrosylated heme proteins
US6187744B1 (en) 1992-03-11 2001-02-13 Michael W. Rooney Methods and compositions for regulating the intravascular flow and oxygenating activity of hemoglobin in a human or animal subject
US5389675A (en) 1992-03-27 1995-02-14 The United States Of America As Represented By The Department Of Health And Human Services Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents
US5814666A (en) 1992-04-13 1998-09-29 The United States As Represented By The Department Of Health And Human Services Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
US5525357A (en) 1992-08-24 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US5405919A (en) * 1992-08-24 1995-04-11 The United States Of America As Represented By The Secretary Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders
US5385940A (en) 1992-11-05 1995-01-31 The General Hospital Corporation Treatment of stroke with nitric-oxide releasing compounds
US5427797A (en) 1993-04-06 1995-06-27 Brigham And Women's Hospital Systemic effects of nitric oxide inhalation
JPH0753358A (ja) 1993-08-17 1995-02-28 Teijin Ltd 吸入剤
US6087479A (en) 1993-09-17 2000-07-11 Nitromed, Inc. Localized use of nitric oxide-adducts to prevent internal tissue damage
US5728705A (en) 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
US5840759A (en) 1993-10-08 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents
ATE194769T1 (de) 1993-10-08 2000-08-15 Us Health Verwendung von stickstoffoxid freisetzenden verbindungen als arzneimittel zur strahlungssensibilisation fur hypoxische zellen
GB9320978D0 (en) 1993-10-12 1993-12-01 Higenbottam Timohy W Nitric oxide treatment
JPH09508097A (ja) * 1993-11-02 1997-08-19 アメリカ合衆国 虚血再灌流傷害における保護剤としての酸化窒素放出化合物の使用
GB9804469D0 (en) 1998-03-02 1998-04-29 Univ Aberdeen Antiviral composition
US6709681B2 (en) 1995-02-17 2004-03-23 Aberdeen University Acidified nitrite as an antimicrobial agent
WO1995022335A1 (en) 1994-02-21 1995-08-24 Aberdeen University Acidified nitrite as an antimicrobial agent
US5648101A (en) 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
US6063407A (en) 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
AU5368296A (en) 1995-03-24 1996-10-16 Brigham And Women's Hospital Nitrosylated blood substitutes
US5823180A (en) 1995-04-03 1998-10-20 The General Hospital Corporation Methods for treating pulmonary vasoconstriction and asthma
US6627738B2 (en) 1995-09-15 2003-09-30 Duke University No-modified hemoglobins and uses therefor
US6153186A (en) * 1995-09-15 2000-11-28 Duke University Medical Center Red blood cells loaded with S-nitrosothiol and uses therefor
US6197745B1 (en) 1995-09-15 2001-03-06 Duke University Methods for producing nitrosated hemoglobins and therapeutic uses therefor
US6258032B1 (en) 1997-01-29 2001-07-10 William M. Hammesfahr Method of diagnosis and treatment and related compositions and apparatus
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
PT914103E (pt) 1996-04-05 2006-09-29 Gen Hospital Corp Tratamento de uma hemoglobinopatia
US5770645A (en) 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US6057367A (en) 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US5958427A (en) 1996-11-08 1999-09-28 Salzman; Andrew L. Nitric oxide donor compounds and pharmaceutical compositions for pulmonary hypertension and other indications
US5912019A (en) 1997-02-07 1999-06-15 Musc Foundation For Research Development Compounds for reducing ischemia/reperfusion injury
BR9811473A (pt) 1997-07-11 2001-12-26 Univ Johns Hopkins Med Infecção por rinovìrus inibida por óxido nìtrico
US6796966B2 (en) 1997-10-15 2004-09-28 Jeffrey E. Thomas Apparatus, and kits for preventing of alleviating vasoconstriction or vasospasm in a mammal
US6358536B1 (en) 1997-10-15 2002-03-19 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
US5994444A (en) 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US6656452B1 (en) 1997-10-21 2003-12-02 The General Hospital Corporation Use of inhaled NO as anti-inflammatory agent
ATE277038T1 (de) 1997-12-23 2004-10-15 Amersham Health As Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung
AU2479099A (en) 1998-01-28 1999-08-16 Seatrace Pharmaceuticals, Inc. Topical vasodilatory gel composition and methods of use and production
US6103275A (en) * 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
US20070086954A1 (en) 1998-11-23 2007-04-19 Miller Christopher C Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
CA2254645A1 (en) 1998-11-23 2000-05-23 Pulmonox Medical Corporation Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
GB9905425D0 (en) 1999-03-09 1999-05-05 Queen Mary & Westfield College Pharmaceutical composition
US20050142218A1 (en) 2000-03-09 2005-06-30 Queen Mary & Westfield College Pharmaceutical composition containing nitrate source and an acidifying agent for treating skin ischaemia
WO2000056863A1 (en) 1999-03-19 2000-09-28 Agritope, Inc. Banana and melon promoters for expression of transgenes in plants
US6187332B1 (en) 1999-06-14 2001-02-13 Wisconsin Alumni Research Foundation Acidic buffered nasal spray
CA2680378C (en) 1999-08-02 2013-09-24 Duke University Method for determining physiological effects of hemoglobin
JP2003506394A (ja) 1999-08-10 2003-02-18 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 視力の保持を容易にするために視神経、脈絡膜、および網膜の血流を増大させるための方法
US6314956B1 (en) 1999-09-08 2001-11-13 Duke University Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders
CA2323008C (en) 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
US6612306B1 (en) 1999-10-13 2003-09-02 Healthetech, Inc. Respiratory nitric oxide meter
DE19960404A1 (de) 1999-12-15 2001-07-05 Messer Austria Gmbh Gumpoldski Exspirationsabhängige Gasdosierung
US6476037B1 (en) 2000-03-23 2002-11-05 The Regents Of The University Of California L-arginine and phosphodiesterase (PDE) inhibitor synergism
ES2232613T3 (es) 2000-04-26 2005-06-01 Cellegy Pharmaceuticals, Inc Formulaciones y metodos de utilizacion de agentes mimeticos del oxido nitrico contra un fenotipo celular maligno.
DE10025202A1 (de) 2000-05-20 2001-11-29 Messer Austria Gmbh Gumpoldski Gasdosiergerät mit Katheter
JP4181290B2 (ja) 2000-06-12 2008-11-12 学校法人早稲田大学 ヘモグロビン小胞体の光還元法
US6601580B1 (en) 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
GB0021317D0 (en) 2000-08-30 2000-10-18 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
AU8852301A (en) 2000-09-01 2002-03-13 Meir S Sacks Compositions and methods for inducing vasorelaxation
GB0022084D0 (en) 2000-09-08 2000-10-25 Univ Aberdeen Treatment of multiply antibiotic-resistant organisms
ATE462424T1 (de) 2000-10-16 2010-04-15 Univ Duke Therapeutische anwendung von zerstäubtem s- nitrosoglutathion bei zystischer fibrose
CA2421885A1 (en) 2000-10-27 2002-05-02 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7335181B2 (en) 2000-12-26 2008-02-26 Pulmonox Technologies Corporation Nitric oxide decontamination of the upper respiratory tract
JP4430867B2 (ja) 2001-01-16 2010-03-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 基材／血液境界面で、ｉｎｓｉｔｕで、生体触媒により生じる、生体疑似的な（ｂｉｏｍｉｍｅｔｉｃ）一酸化窒素の生成
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US6676855B2 (en) 2001-08-02 2004-01-13 Duke University Use of a blood-flow decrease preventing agent in conjunction with insufflating gas
GB0119011D0 (en) 2001-08-03 2001-09-26 Univ Aberdeen Treatment of nail infections
US7025869B2 (en) 2001-09-05 2006-04-11 Cyterra Corporation Nitric oxide delivery system
GB0125222D0 (en) 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
US6472390B1 (en) 2001-11-13 2002-10-29 Duke University Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
US20050164915A1 (en) 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
EP1336602A1 (de) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrat-Prodrugs zur Freisetzung von Stickstoffmonoxid in kontrollierter und selektiver Weise sowie deren Verwendung zur Prävention und Behandlung inflammatorischer, ischämischer und proliferativer Erkrankungen
US20030203915A1 (en) 2002-04-05 2003-10-30 Xinqin Fang Nitric oxide donors, compositions and methods of use related applications
JP2005527834A (ja) 2002-05-29 2005-09-15 デューク・ユニバーシティー 血液ガス中の一酸化窒素の測定およびそれに基づく処置
US7241350B2 (en) * 2002-12-03 2007-07-10 Greenkote (Israel) Ltd. Corrosion resistant poly-metal diffusion coatings and a method of applying same
CA2509817C (en) 2002-12-12 2014-11-04 Duke University Forming iron nitrosyl hemoglobin
SE0300971D0 (sv) 2003-04-03 2003-04-03 Aga Ab Nitric oxide in treatment of inflammation
EP1653978B1 (de) * 2003-07-09 2020-06-03 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Vervendung von nitritsalzen zur behandlung von cardiovaskulären erkrankungen
US7329641B2 (en) 2003-10-30 2008-02-12 Temple University Of The Commonwealth System Of Higher Education Blood substitutes
AU2005244078A1 (en) 2004-05-11 2005-11-24 Pulmonox Technologies Corporation Intermittent dosing of nitric oxide gas
US7362274B1 (en) 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20060088583A1 (en) 2004-10-25 2006-04-27 Oxygenix Co., Ltd. Artificial oxygen carrier containing preventive agents of metHb formation
EP1863503B1 (de) 2005-03-07 2019-05-22 Sangart, Inc. Zusammensetzung zur abgabe von kohlenmonoxid (co) und stickoxid (no) an gewebe unter verwendung von heme-proteinen als träger
WO2006113540A2 (en) 2005-04-14 2006-10-26 Duke University Use of ntrosylated hemoglobin
US7604291B2 (en) * 2005-04-20 2009-10-20 Vitito Christopher J Vehicle entertainment system incorporated within the armrest/console of a vehicle with a swivel monitor mounting structure
US8790715B2 (en) 2006-02-16 2014-07-29 Ino Therapeutics Llc Method and apparatus for generating nitric oxide for medical use
EP2076537B1 (de) 2006-10-06 2018-08-22 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Prävention von gewebeischämie, damit in zusammenhang stehende verfahren und zusammensetzungen
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
US20160008394A1 (en) 2013-02-28 2016-01-14 Aires Pharmaceuticals, Inc. Inorganic nitrite to improve cardiopulmonary hemodynamics

Also Published As

Publication number Publication date
AU2004257693B8 (en) 2009-08-13
JP2007528852A (ja) 2007-10-18
WO2005004884A3 (en) 2005-04-21
CA2537222A1 (en) 2005-01-27
EP1648475A2 (de) 2006-04-26
US9675637B2 (en) 2017-06-13
ES2294543T3 (es) 2008-04-01
DE602004008927T2 (de) 2008-06-05
JP2007528855A (ja) 2007-10-18
US20170281673A1 (en) 2017-10-05
EP1653978A1 (de) 2006-05-10
EP1653978B1 (de) 2020-06-03
CA2536827A1 (en) 2005-01-20
ATE372777T1 (de) 2007-09-15
US20100247682A1 (en) 2010-09-30
US20070154569A1 (en) 2007-07-05
AU2004255268B2 (en) 2010-04-01
JP5564157B2 (ja) 2014-07-30
US9700578B2 (en) 2017-07-11
AU2004257693A1 (en) 2005-01-27
US20150125553A1 (en) 2015-05-07
CA2536827C (en) 2014-09-16
AU2004255268A1 (en) 2005-01-20
US20120195983A1 (en) 2012-08-02
US9387224B2 (en) 2016-07-12
US8927030B2 (en) 2015-01-06
EP1648475B1 (de) 2007-09-12
WO2005004884A2 (en) 2005-01-20
JP2012092129A (ja) 2012-05-17
WO2005007173A1 (en) 2005-01-27
JP5564158B2 (ja) 2014-07-30
AU2004257693B2 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
DE602004008927D1 (de) Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen
Zurita et al. The pig model of chronic paraplegia: a challenge for experimental studies in spinal cord injury
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
JP2004532215A (ja) 睡眠時の自律的安定性に関するカンナビノイドの機能的役割
RU2345713C1 (ru) Способ прогнозирования течения раневого процесса при глубоких отморожениях нижних конечностей
Staszelis et al. The effect of ketamine on delta-range coupling between prefrontal cortex and hippocampus supported by respiratory rhythmic input from the olfactory bulb
Velmahos et al. Physiologic monitoring of circulatory dysfunction in patients with severe head injuries
RU2230521C2 (ru) Способ формирования большой затылочной цистерны при синдроме арнольд-киари
Hartman et al. The relative value of pectin solution in shock
RU2414173C1 (ru) Способ лечения субдуральной гематомы
ABAKUMOW et al. Initial depression and normalization of higher extremity oxygenation in an autistic girl due to kinesitherapy using an adapted high altitude protection suit: a case study
RU2133629C1 (ru) Способ уменьшения хронической гипоксии тканей
RU2178288C2 (ru) Способ лечения заболеваний нервной системы
Gehlot et al. Valsalva Manoeuvre: A Versatile Diagnostic and Therapeutic Method
RU2248818C1 (ru) Способ лечения подростков с гипоталамическим синдромом пубертатного периода
RU2232014C1 (ru) Способ лечения сенсоневральной тугоухости
Dias et al. Effects of jugular vein occlusion on cardiovascular parameters in horses during exercise on a treadmill
RU2632619C1 (ru) Способ лечения больных артериальной гипертонией
Bloch et al. Teratoma of the conus medullaris
RU2604819C1 (ru) Способ лечения церебральной ишемии новорожденных
Mate et al. Monitoring distal limb perfusion using near-infrared spectroscopy in patients on intra-aortic balloon pump
RU2481131C1 (ru) Способ лечения гипоталамического синдрома пубертатного периода
RU2019209C1 (ru) Способ лечения синдрома длительного сдавления
UA39913U (uk) Спосіб мініінвазивного хірургічного лікування кіст підшлункової залози із застосуванням озоноквантової терапії

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: HUNTER, CHRISTIAN J., BETHESDA, MD, US

Inventor name: POWER, GORDON G., REDLANDS, CA, US

Inventor name: PATEL, RAKESH P., BIRMINGHAM, LA, US

Inventor name: KIM-SHAPIRO, DANIEL B., WINSTON-SALEM, NC, US

Inventor name: PLUTA, RYSZARD, BETHESDA, MD, US

Inventor name: CANNON III, RICHARD O., POTOMAC, MD, US

Inventor name: LEFER, DAVID J., SHREVEPORT, LA, US

Inventor name: GLADWIN, MARK T., WASHINGTON, DC, US

Inventor name: OLDFIELD, EDWARD H., PHILOMONT, VA, US

Inventor name: SCHECHTER, ALAN N., BETHESDA, MD, US

8364 No opposition during term of opposition